NCT02139943 – A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus Posted on May 9, 2024 by Jessica Ritchie -
NCT02846545 – SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes Posted on August 5, 2023 by tsuperadmin -
The YODA Project